Dr Frank Lee has over four decades of R&D experience working in drug metabolism and pharmacokinetics (DMPK), drug candidate selection, and first-in-human (FIH) clinical trials strategy for some of the world′s largest pharmaceutical companies, including Syntex, Glaxo, Dupont, Millennium, and Takeda. During his career, Frank has participated in the development of several brand-name drugs such as Naprosyn^®, Anaprox^®, and Ticlid^®. Prior to his retirement in 2012, he held the position of VP of DMPK at Takeda, where he oversaw DMPK and participated in the drug candidate selection and FIH strategy. He is passionate about putting Taiwanese biotech companies on the global stage and believes that pioneering research and advanced technologies are the keys to discovering new medicines for urgent, unmet medical needs. Frank has a PhD in Medicinal Chemistry from the University of California, San Francisco.